respectively. Furthermore, HANSIZHUANG was respectively recommended by theCSCO Guidelines for Small Cell Lung Cancer, theCSCO Guidelines for Non-Small Cell Lung Cancer, theCSCO Guidelines for Esophageal Cancer, theCSCO Guidelin...
respectively. Furthermore, HANSIZHUANG was respectively recommended by the CSCO Guidelines for Small Cell Lung Cancer, the CSCO Guidelines for Non-Small Cell Lung Cancer, the CSCO Guidelines for Esophageal Cancer, the CSCO Guidelines for Colorectal Cancer, the CSCO Clinical Practice Guidelines on Immun...
Potential solutions for manufacture of CAR T cells in cancer immunotherapy CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies ...
today announced its latest breakthrough in cancer treatment. The company's non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300, showcases a novel approach to targeting cancer cells while preserving healthy tissues....
While high-throughput drug screening offers possibilities to profile phenotypic responses of hundreds of compounds, elucidation of the cell context-specific mechanisms of drug action requires additional analyses. To that end, we developed a computational target deconvolution pipeline that identifies the key...
The emergence of ipilimumab and CAR-T cell therapy is an epoch-making turning point in cancer immunotherapy, which is called a breakthrough in 2013 by Science [25]. Currently, a variety of immunotherapies have been approved for cancer treatment (Table 1). Therefore, as a promising therapeutic...
(PR), respectively, showing considerable therapeutic efficacy.39In a phase 1 non-randomized clinical trial involving 66 patients with advanced HER2/neu-positive breast cancer, a plasmid DNA vaccine encoding the intracellular domain of HER2/neu elicited an antigen-specific T cell response that ...
The goal is to induce a strong response by the adaptive immune system, resulting in potent antitumor T- and B-cell responses. The hope is that these primed immune effectors will eradicate any remaining cancer cells in vivo.40 Clinical trials of these concepts have used a great variety of ...
breakthrough therapy designation; HR, hazard ratio; mHSPC, metastatic hormone-sensitive prostate cancer; NET, neuroendocrine tumors; NSCLC, non-small cell lung cancer; PFS, progression-free survival; RCC, renal cell carcinoma; RCT, randomized clinical trial; RR, response rate; SCLC, small cell ...
Immune checkpoint inhibitors including PD/PDL-1 and CTLA-4 inhibitors are a major breakthrough in the management of cancer [73]. These drugs activate T-cells and enhance the immune response against malignant cells, but at the same time can cause autoimmune phenomena including autoimmune endocrinopa...